Product Description
For Relapsing-remitting Multiple Sclerosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02744222)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocad
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Multiple Sclerosis, Relapsing-Remitting
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BCD-054-1 | P1 |
Completed |
Healthy Volunteers |
2015-10-01 |
2019-03-20 |
Treatments |
|
| BCD-054-2 | P3 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2018-11-23 |
62% |
2021-09-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |